Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NanoViricides Inc NNVC

Healthcare Biotechnology
NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.


NYSEAM:NNVC - Post by User

NanoViricides Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by jmhollenon Sep 27, 2005 12:14pm
23 Views
Post# 9615205

NNVC - NanoViricides, Inc. - DD:

NNVC - NanoViricides, Inc. - DD: NNVC (AIDS, Herpes, & Bird Flu Cures/Treatments) - full financial disclosure: https://www.otcstockinfo.com/repository/655752/655752_FR3.pdf .
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities

Stockhouse Logo
Support
Legal
Follow Us
Stockhouse.com is owned by Stockhouse Publishing Ltd. © 2019 Stockhouse Publishing Ltd. All rights reserved. Financial Market Data powered by Refinitiv. All rights reserved. Quotes and other data delayed by 15 minutes for NYSE/AMEX/NASDAQ, 20 minutes for TSX/TSX-V unless otherwise indicated. Google Play and the Google Play logo are trademarks of Google Inc. The Apple logo and iTunes are trademarks of Apple Inc., registered in the U.S. and other countries.